Spoken Alpha
Alkermes plc.
Alkermes plc develops and commercializes biopharmaceutical products for neuroscience disorders. The company markets proprietary medications for schizophrenia, bipolar I disorder, narcolepsy, alcohol dependence, and opioid dependence, while also licensing its drug-delivery technologies to partners like Janssen and Biogen.
Alkermes plc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $7.69B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 26, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ALKS.
$ curl https://api.spokenalpha.com/v1/companies/ALKSFAQ
Spoken Alpha indexes ALKS's earnings call transcripts at https://spokenalpha.com/companies/ALKS. Each call links to attributed speakers and parsed analyst Q&A. Alkermes plc.'s own investor relations page is at https://investor.alkermes.com/.
Alkermes plc. (ALKS) held its most recent earnings call on 2026-07-28, covering fiscal Q2 2026.
Alkermes plc. (ALKS) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-26 | — | $-0.08 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-27 | $0.52 | $-0.04 | +100.0% | $496.0M | — | — | EODHD |
| Q1 FY2026 | 2026-05-04 | $0.38 | $-0.04 | +100.0% | $392.9M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $0.29 | $0.41 | -29.3% | $384.5M | — | — | EODHD |
| Q3 FY2025 | 2025-10-27 | $0.65 | $0.39 | +66.7% | $394.2M | — | — | EODHD |
| Q2 FY2025 | 2025-07-28 | $0.68 | $0.40 | +70.0% | $390.7M | — | — | EODHD |
| Q1 FY2025 | 2025-04-30 | $0.29 | $0.24 | +20.8% | $306.5M | — | — | EODHD |
| Q4 FY2024 | 2025-02-11 | $1.05 | $0.76 | +38.2% | $430.0M | — | — | EODHD |
| Q3 FY2024 | 2024-10-23 | $0.73 | $0.71 | +2.8% | $378.1M | — | — | EODHD |
| Q2 FY2024 | 2024-07-23 | $0.70 | $0.71 | -1.4% | $399.1M | — | — | EODHD |
| Q1 FY2024 | 2024-04-30 | $0.43 | $0.58 | -25.9% | $350.4M | — | — | EODHD |
| Q4 FY2023 | 2024-02-14 | $0.22 | $0.51 | -56.9% | $377.5M | — | — | EODHD |
| Q3 FY2023 | 2023-10-24 | $0.64 | $0.43 | +48.8% | $380.9M | — | — | EODHD |
| Q2 FY2023 | 2023-07-25 | $0.55 | $0.64 | -14.1% | $617.4M | — | — | EODHD |
| Q1 FY2023 | 2023-04-25 | $0.01 | $-0.01 | +100.0% | $287.6M | — | — | EODHD |
| Q4 FY2022 | 2023-02-15 | $0.14 | $0.05 | +100.0% | $304.7M | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $0.02 | $0.03 | -33.3% | $252.4M | — | — | EODHD |
| Q2 FY2022 | 2022-07-26 | $0.06 | $0.05 | +20.0% | $276.2M | — | — | EODHD |
| Q1 FY2022 | 2022-04-26 | $0.12 | $0.03 | +100.0% | $278.5M | — | — | EODHD |
| Q4 FY2021 | 2022-02-15 | $0.23 | $0.08 | +100.0% | $324.5M | — | — | EODHD |
Source: EODHD. ALKS reported actuals as published; sparse fields render as —.